CEO & Co-Founder
Co-Founder
Chief Commercial Officer
Vice President of Sales
Director of Product Development
AVP, Clinical Strategy & Customer Relations
Area Vice President, Sales
Area Vice President, Sales
Dr. David T. Durack is Consulting Professor of Medicine at Duke University and was previously Senior Vice President, Corporate Medical Affairs and Chief Medical Officer at Becton Dickinson & Co.
Dr. Durack earned his medical degree from the University of Western Australia with Honors and went on to Oxford University as a Rhodes Scholar. His internship and residencies were conducted at the Radcliffe Infirmary in Oxford and the Royal Postgraduate Medical School at Hammersmith Hospital in London. He began his clinical career in the USA as Chief Resident and junior faculty member in the Department of Medicine at the University of Washington in Seattle. Subsequently he was recruited to Duke University, where he served as Chief of the Division of Infectious Diseases and International Health, Professor of Medicine, and Professor of Microbiology and Immunology.
Dr. Durack has broad and deep expertise in the area of infectious diseases. His research career began at Oxford University, where his doctoral thesis was entitled “Experimental Endocarditis”. Since then he and his colleagues have conducted an extensive series of research studies on the pathogenesis and chemotherapy of bacterial and fungal infections, while continuing clinical practice in Internal Medicine and Infectious Diseases. Dr. Durack has published more than 230 articles and textbook chapters and co-edited several textbooks.
Dr. Durack is a Fellow of the Royal College of Physicians (UK), the Royal Australasian College of Physicians, and the American College of Physicians. He has been elected to the American Society for Clinical Investigation, the Council of the Infectious Diseases Society of America, and the American Academy of Microbiology. He has served on an FDA Review Panel, the Joint Commission Resources Board of Directors, and as Chairman of the Board, ASM Resources. He is currently a Director for PixelEXX Systems Inc. He has 17 years’ experience as a Medical Affairs functional leader and executive officer in the medical devices and diagnostics industry.
Garheng Kong is the founder and managing partner of HealthQuest Capital. He has over two decades of experience in the healthcare field as an investor, physician, scientist, and engineer.
Dr. Kong’s investments and board directorships have resulted in the IPOs of Cempra (CEMP), Alimera (ALIM), Applied Genetic Technology Corp. (AGTC), Proteon (PRTO), Histogenics (HSGX) and TransEnterix (TRXC). He has also had board roles in many M&A transactions that include Calibra Medical (J&J), Cellective (AstraZeneca), Serenex (Pfizer), Athenix (Bayer), NovaMin (GSK), Aldagen (Cytomedix), Salveo Specialty Pharmacy (Catamaran) and SARCode (Shire). Dr. Kong has been asked to Chair the board of seven companies as well.
Dr. Kong is a member of the board of directors of Laboratory Corporation of America (LabCorp, NYSE:LH) and Duke University Medical Center as well as Alimera Sciences (ALIM), Castle Biosciences, Cempra (CEMP), First Aid Shot Therapy, Histogenics (HSGX), Strongbridge (SBBP), Trice Medical and VirMedica. Dr. Kong’s interests and industry footprint are broad as he also serves on the board of SEBIO, Corporate Chaplains of America, Cure Network Ventures, and advises IDEO Palo Alto and numerous industry groups. He has also served on the Duke Medical Center Institutional Review Board (IRB) and as faculty at the Duke Fuqua School of Business as a senior scholar.
Dr. Kong received two undergraduate degrees, in chemical engineering and biological sciences, from Stanford University, which he attended on an athletic scholarship. He then earned his MD, PhD and MBA from Duke University, graduating at the top of his class in each instance. His early career included stints at GlaxoSmithKline, McKinsey & Co. and medical device startup TherOx. Dr. Kong has been founder and CEO of two successful biopharma companies (Cellective and Viamet). Prior to HealthQuest, he was a general partner at Intersouth Partners and a general partner at Sofinnova Ventures.
Paul Enever is a managing director at Canepa Healthcare. Before joining Canepa, Paul was a partner at McKinsey and Company. In his 12 years at McKinsey, he advised leading organizations across the bio-pharma, med-tech, hospital, and healthcare services industries primarily in the U.S. and Europe as well as private equity firms specializing in healthcare. Paul’s work focused on growth strategy, sales and marketing, and licensing and acquisition. Previously, Paul worked within the R&D organization at Sandoz Pharmaceuticals and MIT’s Biotechnology Process Engineering Center.
He sits on the Boards of Directors of Cardiva Medical, Dune Medical Devices, and Magnolia Medical Technologies.
Paul has a B.S. in chemical engineering from Rensselaer Polytechnic Institute and a Ph.D. in chemical engineering from the University of Minnesota where he studied wound healing and tissue engineering. For his work, Paul was the recipient of both a National Science Foundation Graduate Fellowship and the Whitaker Foundation Graduate Fellowship in Biomedical Engineering.
Josh is a Venture Partner at Split Rock Partners, and also serves as a Venture Partner at SightLine Partners. He has been with Split Rock since 2004 and with SightLine since 2014. Mr. Baltzell has over 20 years of experience in the healthcare industry.
Prior to his tenure in the venture capital industry, Josh held roles as an investment banker at Piper Jaffray Companies from 2000 to 2002, where he focused primarily on mergers and acquisitions in the medical device sector as well as various marketing and business development positions with SCIMED and Boston Scientific. Josh currently serves on the boards of Colorescience, EBR Systems, Inc., Entellus Medical (NASDAQ: ENTL), Histogenics Corporation (NASDAQ: HSGX) and Nanocyte Medical. Josh is also a co-inventor of the DentaDish.
Josh’s previous investments and board affiliations have resulted in several M&A transactions including Ardian (Medtronic), Dfine (Merit Medical), RF Surgical (Medtronic), Skinmedica (Allergan) and Tarsus (Integra Lifesciences).
Josh holds a B.A. in Economics from St. Olaf College and an M.B.A. from the University of Minnesota’s Carlson School of Management.
Randy is a Partner and co-founder of HealthQuest Capital, a venture capital firm focused on growth investments into companies transforming the value of healthcare. Prior to moving into venture capital, Randy was a successful medtech entrepreneur for many years.
Randy’s industry successes include starting NovaMin Technology, Inc. leading it through financing, growth and eventual acquisition by GlaxoSmithKline; a turn-around of USBiomaterials Corp, leading bone-grafting products company from perennial money-loser to profitability (now known as NovaBone Products, LLC); and a member of the early management team at LensCrafters as it emerged from start-up to market leader. He spent the first half of his career in consumer products marketing, starting in brand management at Procter & Gamble in Cincinnati. He is a graduate of Georgia Tech.
At HealthQuest Randy currently serves on the Boards of Magnolia Medical Technology, Trice Medical, Vestagen Protective Technologies, and Springbuk and is Board observer at CareMetx.
Ron Lowy serves on the boards and as an advisor to multiple medical device, education and information technology companies.
Mr. Lowy is currently the Executive Chairman of PharmaJet, Inc, a Needle-Free injection technology company. He also serves as Chairman of FluoroFinder, a developer and provider of cloud-based medical research tools and Chairman of the Advisory Board of Phase Holographic imaging, a provider of non-invasive cell imaging technology.
Mr. Lowy previously served as the President and CEO of the Biosciences division of Thermo Fisher Scientific, Inc. Prior to that he was President of Global Connectivity Solutions for ADC Telecommunications. He also served as President and Chief Operating Officer at the KRONE Group.
Mr. Lowy spent the first 15 years of his career in operations, technology and general management positions at GE Healthcare where he was active in GE’s development of Computerized Tomography (CT), Magnetic Resonance (MR) and multiple imaging technologies.
Mr. Lowy holds a Bachelor of Science degree in Mechanical Engineering from the University of New Hampshire and an MBA from the University of Wisconsin.
Mr. Meister is co-founder of Liberty Lane Partners, LLC, a private investment company with investments in healthcare, technology, and distribution-related industries and Perspecta Trust, a trust company that provides trust and investment services.
Mr. Meister recently served as President of MacAndrews & Forbes Incorporated. He previously served as Chairman and CEO of inVentiv Health (now Syneos Health), a leading provider of commercial, consulting and clinical research services to the pharmaceutical and biotech industries.
Previously, Mr. Meister served as Chairman of the Board of Thermo Fisher Scientific, Inc. and Vice Chairman of Fisher Scientific International, Inc. prior to Fisher’s merger with Thermo.
During Mr. Meister’s tenure as an executive officer of Fisher Scientific, from 1991 to 2006, the company’s revenue and operating income grew at a compound annual growth rate of 15% and 23% respectively as operations grew from two countries to 27 and sales expanded into 140 countries worldwide.
Earlier in his career, Mr. Meister served in a number of executive leadership positions at Wheelabrator Technologies Inc., The Henley Group Inc., and AlliedSignal Inc. (now Honeywell International, Inc.). He began his career with Ford Motor Company.
Mr. Meister holds a Bachelor of Arts degree from the University of Michigan and an MBA from Northwestern University. He is a director of Aptiv PLC, Scientific Games Corporation, Quanterix Corporation; co-chair of the University of Michigan’s Life Sciences Institute External Advisory Board, chair of the Provost Advisory Board and serves on the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University.
Ben Elowitz is co-founder and CEO of Wetpaint, a technology and media company that specializes in building audiences from the social web. The company’s Wetpaint Entertainment news and celebrity website reaches 12 million unique users per month.
Prior to Wetpaint, Mr. Elowitz co-founded Blue Nile (NILE), the largest online retailer of luxury goods; oversaw the $150 million commercial products business for fitness equipment manufacturer Precor; and was also an early employee at Fatbrain.com (FATB), an e-commerce company that went public in 1998 and was sold to Barnes & Noble in 1999.
Mr. Elowitz is a recognized a thought leader on the subject of entrepreneurship and the media industry. He is the author of the Digital Quarters blog and the Media Success newsletter open to senior industry executives only. He has also been an angel investor in various companies such as BetFair (BET:LN), Minted, Cheezburger Networks, and JustFab (IB Holdings); and is a frequent conference speaker on media, social content, and entrepreneurship.
Dennis Capovilla is a Silicon Valley executive whose 25+ year career has included senior management positions at Fortune 100, microcap and startup companies where he has garnered recognition for his entrepreneurial insight and strategic acumen. Mr. Capovilla currently serves on numerous boards and is Executive Director at Powis Inc.
As President and CEO of Southwall Technologies, an innovative thin film technology company focused on energy efficiency products, Mr. Capovilla restructured and turned around this underperforming company. He revitalized R&D, expanded sales, drove M&A activities and took the company on NASDAQ. He ultimately executed the strategic exit with the successful sale to Solutia; multiplying shareholder value by 5x in a short period of time.
At Palm, Mr. Capovilla restructured the enterprise go-to-market strategy and created a medical vertical for mobile clinical trials. At Fatbrain, a pioneering ecommerce company, Mr. Capovilla oversaw explosive growth and played a key role in the company’s NASDAQ IPO. As President and CEO of Fatbrain, he was named Entrepreneur of the Year for Technology by the Silicon Valley Business Journal in 2000. He later achieved a successful exit for Fatbrain by engineering the sale of the company to Barnes & Noble.
Previous to this role, Mr. Capovilla served as Director of Apple’s Imaging Division where he led a $250M division and held numerous sales leadership positions with the Xerox Corporation.
Jack Krouskup has over 35 years of experience serving clients in a variety of industries. His primary focus over the past ten years was clients in the chemical manufacturing, healthcare and life sciences industries. Mr. Krouskup was previously partner-in-charge of Deloitte’s Northern California financial services practice where he served on Deloitte’s financial services advisory committee. He served as advisory partner on a number of large Northern California clients, and used his years of experience to support Deloitte teams and provide insights to client management and audit committees. Mr. Krouskup also helped lead an internal Deloitte integration team to effect an international merger of major accounting firms.
Mr. Krouskup has years of boardroom experience representing Deloitte with numerous global and highly complex organizations. Consequently, he has extensive corporate governance background and deep familiarity with board and audit committee best practices. Additionally, he has served numerous early stage companies in both financial services and life sciences including several IPO and merger transactions. He has broad experience in Securities and Exchange Commission (SEC) matters and other accounting and reporting requirements including initial public offerings, debt and equity registrations, responding to SEC comment letters and foreign statutory audit filings. Jack assisted several companies (including McKesson and Huntsman Corporations) in their initial year of compliance with internal controls related to financial reporting (Sarbanes 404).
Mr. Krouskup previously concentrated on financial services clients and served as a technical advisor to several financial services industry groups. He served as lead client service partner for the San Francisco Federal Home Loan Bank and also worked with Federal regulators on the liquidation/receivership audits of several failed institutions.
Mr. Krouskup’s extensive experience in the areas of mergers and acquisitions, including due diligence evaluations in financial services, healthcare and distribution sectors bring significant value Magnolia Medical Technologies.
Nate McLemore is a Managing Director for Columbia Pacific Management, where he is responsible for the firm’s healthcare investments with a primary focus on hospitals and senior housing in Asia. Mr. McLemore is a Board Member of Columbia Asia, a healthcare system with 23 hospitals and clinics in India, Indonesia, Malaysia, and Vietnam. He also serves on the Board of Remote Medical International , a medical and rescue services company specializing in providing care in remote areas. In China, Mr. McLemore is working to expand Kaijian Healthcare, the first foreign-owned operator of senior housing in the country, as well as pursuing several projects to build and operate hospitals.
Prior to joining Columbia Pacific, Mr. McLemore was a General Manager in Microsoft’s Health Solutions Group, where he was responsible for international sales, business development, M&A, professional services, policy and compliance. Mr. McLemore joined Microsoft from RelayHealth, where he served as Vice President of Business Development for this leader in online, doctor-patient communication, which was acquired by McKesson in 2006.
Earlier in his career, Mr. McLemore headed CFM’s federal lobbying practice, where he represented health care systems and technology companies before Congress and the Executive Branch. Mr. McLemore has a BA in Political Science from Willamette University and an MBA from the University of California at Berkeley’s Haas School of Business. He enjoys spending time with his wife and two young sons and is an avid skier, runner, boater, and an aspiring golfer.
John Wallace is a results-oriented senior executive with over 30 years of global experience in management, operations, finance, international business and manufacturing. He has a diverse background and a proven track record of strong leadership.
Mr. Wallace was the Chief Operating Officer at Nova Biomedical Corporation, a world leader in the development, marketing and manufacture of proprietary blood diagnostic products, consumer healthcare diabetes products and medical devices for Fortune 500 and emerging companies. Nova is a pioneer in the development of biosensors for whole blood diagnostics to support the care of critically ill patients. With more than $175 million in revenue run rate and in excess of $35 million in operating profits, Nova was built by the strength and depth of its 750+ employees and sweat equity. Mr. Wallace led the management of strategic alliances and served on the Board of Directors, the Corporate Quality Committee and was the Chairman of the Operating Committee. Nova experienced consistent record revenue and earnings growth during his tenure.
Mr. Wallace has served on numerous Boards including on the Board of Directors and as Chairman of the Audit Committee of Zoll Medical Inc. (NASDAQ), a world leader in resuscitation and critical care devices. The Company experienced rapid market expansion and numerous product innovations during his involvement with Zoll. Mr. Wallace played an active role in the acquisition of Zoll by Japan’s Asahi Kasei Corporation in a $2.2 billion cash transaction where Zoll’s management and employees remained intact.
Earlier in his career, Mr. Wallace was a senior executive at Cortex Corporation as well as Numerix Corporation, and also held management positions with Analog Devices Inc., Data General Corporation and Federated Department Stores (Filene’s Division). Currently, Mr. Wallace holds Board positions with Triangle, Inc., Massachusetts Medical Device Industry Council (MassMedic), Discovering Justice/James D. St. Clair Federal Court Education Program, Neighborhood Association of the Back Bay and is a Senior Advisor to Tower Three Medical (an arm of Tower Three Partners – a Greenwich Connecticut-based private equity firm) in the role of Executive Vice President and Chief Operating Officer, where he provides guidance on evaluating potential acquisitions and financial/operational implementation and effectiveness.
Bill Rhodes is Founding Member of Third Day Advisors LLC, a management and strategy advisory firm specializing in helping healthcare and life sciences companies as they consider corporate mergers and acquisitions as part of their growth plans. He is also an Operating Partner with Linden Capital Partners LP, a Chicago-based healthcare private equity firm, where he is responsible for the life sciences and diagnostics sector.
Prior, Mr. Rhodes was with Becton Dickinson and Co. (BD), a Fortune 500, multinational healthcare products corporation, as a named Executive Officer and the Senior Vice President, Business Development and Strategy. He was responsible for corporate strategy and global M&A activities.
Previous to this role, he served as BD’s Worldwide President, BD Biosciences, a 3,000 person, US $1.4 billion segment, responsible for its three business units: Cell Analysis, Discovery Labware and Advanced Bioprocessing. Prior to assuming that role, he was President, Cell Analysis, and before that, VP of Business Development and Strategic Investments, where he held worldwide responsibility for business development activities. He also formed and managed BD Ventures L.L.C., the corporate venture capital fund operated by BD.
Prior to joining BD, Mr. Rhodes held various senior executive roles in business development and technology, for Pfizer, Johnson and Johnson and The William James Company.
Mr. Rhodes also currently serves as Senior Executive in Residence at Cornell University, where he identifies university-based technologies appropriate for business formation, and mentors entrepreneurs. In addition, he is a Clinical Instructor with the Weill Cornell Medical College’s Department of Public Health.
Dr. McDaniel was born on a farm near Muskogee, Oklahoma and attended college on a full wrestling scholarship at Oklahoma State University where he received a Bachelor of Science degree in Physiology. Following graduation, he began studies at the University of Oklahoma School of Medicine and received his Doctor of Medicine degree in 1968. He completed his internship at St. Francis Hospital in Tulsa, Oklahoma in 1969.
After commissioning in the Navy in 1969, Dr. McDaniel served in a variety of locations, including Vietnam, Spain, Japan, Korea, and Hawaii over the course of 30 years. He had a total of five commands, assuming command of Naval Hospital, Charleston, South Carolina, in 1988, which became a key medical facility during Hurricane Hugo in 1989. He was selected as Rear Admiral in 1989. In June, 1990, he became the Surgeon for the U.S. Pacific Command, Camp H.M. Smith, Hawaii. In 1992 he assumed command of the Naval Medical Center, Portsmouth, Virginia, and received his second star there in 1993.
Since retiring from the navy in January, 1997, Dr. McDaniel has worked as a consultant or board member for multiple organizations, including Imatron, Inc.; Center for Naval Analysis; Chairman of a Flag/General Advisory Board to the Applied Physics Laboratory, Johns Hopkins University; and, as a consultant to the Under Secretary of Defense for Personnel and Readiness, the Honorable Rudy de Leon. He served on the U.S. Olympic Committee as the co-chairman for the Sports Medicine 2000 committee from 1997-2000, and was the physician for the U.S. Freestyle Wrestling team in the World Championships in Ankara, Turkey, in 1999, and for the World Cup Freestyle Championships in 2000. He was the Chairman of a Blue Ribbon Panel formed by the CNO for the assessment of the future of National Naval Medical Center, Bethesda, MD, in 2000.
Following the tragedy of 9/11, he became the federal liaison for Johns Hopkins University in preparing their Homeland Security plan. He was a consultant for EADS North America on development of field medical hospitals, and was a part time consultant for EAI Corporation and for Northrup Grumman. He was on the Board of Advisors for Aetna Insurance Company of Hartford, CT, from 2007-2010. He is currently a Board member for Computer Technology Associates, on the Board of Advisors of Haven Behavioral Healthcare, Inc., and on the Board of Directors for Vioguard, Inc., of Seattle, WA. He is Chairman of the Board for DEEC (Diesel Engine Emission Control) of Bellevue, Wa.
Dr. McDaniel was hired by the Commander-in-Chief of the Pacific Fleet in Hawaii to head the advance team into Banda Aceh following the tsunami of December, 2004, preceding USNS Mercy’s arrival. He spent 2 months in Banda Aceh working on issues of public health, then spent almost another month working on Nias Island, Indonesia, following the earthquake there. He has been an extremely active lecturer around the nation about this activity, strongly supporting a movement to continue using military medical assets for medical assist visits around the world. He has given multiple lectures on leadership around the US. He has authored a book about that experience, “Faces of the Tsunami,” which is currently in the process of publication.
Dr. Frank Cockerill currently is the CEO of Analyte Health located in Chicago, Illinois. Analyte Health is a leading digital laboratory testing company providing online laboratory services for sexually transmitted diseases.
Dr. Cockerill is the immediate past Chair of Department of Laboratory Medicine and Pathology, Mayo Clinic, and President and CEO of Mayo Collaborative Services, Inc. (MCSI)/Mayo Medical Laboratories (MML). While at Mayo he also carried a named professorship, the Ann and Leo Markin Professor of Medicine and Microbiology at the Mayo Medical School.
Dr. Cockerill is Board Certified in Internal Medicine and Infectious Diseases (American Board of Internal Medicine) and Clinical Microbiology (American Board of Pathology). He practiced Internal Medicine and Infectious Diseases for over a decade before shifting his focus to Clinical Microbiology. Dr. Cockerill’s research interests have ranged from basic discovery to applied science with a special emphasis on the phenotypic and genotypic identification of antimicrobial resistance.
Dr. Cockerill has authored or co-authored over 150 publications in the medical literature many of which relate to diagnostic testing for infectious diseases. He and his research team at Mayo developed numerous real-time PCR assays, which have significant advantages over conventional culture-based assays, and include the first commercially available rapid PCR test for Anthrax. This work has resulted in 8 US patents, 2 foreign patents and 56 licensed technologies.
As President and CEO of Mayo Collaborative Services, Inc. (MCSI), Dr. Cockerill oversaw the largest for-profit company associated with Mayo Clinic. The major service line of MCSI, Mayo Medical Laboratories (MML), is the third largest provider of esoteric laboratory services in the United States and, in total, serves over 4000 clients in 130 countries.
Dr. Cockerill’s current or recent extramural leadership positions include Chair of the Subcommittee on Antimicrobial Susceptibility Testing, Clinical Laboratory Standards Institute (CLSI), Chair, Microbiology Devices Panel of the Medical Devices Advisory Committee of the US Food and Drug Administration (FDA), Board Member and Program Director, of the Association for Molecular Pathology (AMP), Director, American Clinical Laboratory Association Board; Director, Board of Scientific Counselors of the Centers for Disease Control and Prevention (CDC) and Editor, Journal of Clinical Microbiology.
Finally, Dr. Cockerill has received numerous awards, fellowships and honors including the BD Award for Research in Clinical Microbiology, the Laboratory Public Service National Leadership Award and Fellowship in the American Academy of Microbiology. The BD Award, sponsored by the American Society for Microbiology (ASM), is the highest honor bestowed upon a clinical microbiologist in the United States. The Laboratory Public Service National Leadership recognizes significant contributions to the healthcare of the American public with past recipients including both scientists and US senators and congressmen.
Dr. Goldenbaum is an expert in clinical microbiology and blood culture technology having led a long and distinguished career in both industry and academia.
Dr. Goldenbaum’s industry experience included a variety of leadership roles in R&D at Becton Dickinson (BD) within the Diagnostic Instrument Systems group. He was initially charged with improving and expanding the product line of BACTEC blood culture media. In this role he developed the blood culture media for all generations of the BACTEC blood culture system including radiometric, resin media, non-radiometric and the current fluorescent, non-invasive media.
During his tenue at BD, Dr. Goldenbaum directed a number of R&D areas. These included product development and manufacturing oversight for BD Immunodiagnostics (Directigen lateral flow products), BD Molecular Diagnostics (BD ProbeTec, BD Affirm, etc.), MGIT Mycobacteria detection systems, Phoenix microbial identification and antibiotic sensitivity testing, BBL plated and dehydrated media products, and more.
Dr. Goldenbaum also served as the BD liaison on biowarfare to various United States government agencies including CDC, NIH and USAMRID. In continuing education, Dr. Goldenbaum’s studies included R&D management at the M.I.T. Sloan School of Business, and Biowarfare Preparedness at the National Defense University (National War College), Ft. McNair, Washington D.C.
Throughout his time with BD, Dr. Goldenbaum was highly focused on blood culturing and sepsis. In his role as Head of new technology development, Dr. Goldenbaum evaluated many potential disruptive new diagnostic technologies which involved close engagement with broad range of start-up companies around the world. At the time of his retirement from BD Dr. Goldenbaum was Director of Research and Development at BD Diagnostic Instrument Systems.
Prior to his role at BD, Dr. Goldenbaum was a faculty member in the Department of Biological Science at Southern Illinois University, Edwardsville. Dr. Goldenbaum taught various courses in microbiology, biochemistry, molecular genetics, and directed graduate student research. His direct research focused on bacterial membrane transport mechanisms and exogenous induction of inducible genes in Escherichia coli.
As a faculty member, Dr. Goldenbaum received the Amoco Teaching Excellence Award, and the University Research Scholar Award. Dr. Goldenbaum also served as Acting Chair of the Department of Biological Sciences and was President of the Faculty Senate. He was promoted to Associate Professor and granted tenure. His eighteen-month Sabbatical leave research was supported by a National Science Foundation grant for his position as Adjunct Associate Professor in the Department of Microbiology, Washington University School of Medicine, St. Louis, MO. Here, he worked with Dr. David Kennell on the regulatory role of post-transcriptional modification of E. coli messenger RNA.
Dr. Goldenbaum earned his Ph.D. in microbial physiology and biochemistry at North Carolina State University where his research focused on the role of cyclic AMP in regulation of inducible genes in Escherichia coli. Following graduation, he conducted postdoctoral research in the Department of Biochemistry of the A. B. Chandler School of Medicine, the University of Kentucky, and further postdoctoral research at Florida State University. In both postdoctoral positions he investigated the role of menadione (vitamin K2) in regulation of the Staphylococcus aureuselectron transport chain.
Dr. Goldenbaum is a Fellow of the American Academy of Microbiology and has served as the President of the Maryland Branch of the American Society for Microbiology (ASM). At the national ASM level, Dr. Goldenbaum served to review submitted manuscripts for the Journal of Bacteriology and as a session moderator at national ASM meetings.
Dr. Goldenbaum has United States, European and World patents in the area of blood cultures and sepsis, has authored many publications and grants and has given numerous talks and presentations in the US, Europe and the Orient. Dr. Goldenbaum is now a clinical microbiology consultant (Texas Microbiology Consultants, LLC) for start-up companies in the field of blood cultures and rapid bacterial IDAST (identification, antimicrobial sensitivity testing). He resides in San Antonio, Texas.
Dr. Sexton is a graduate of the Northwestern University School of Medicine and is currently a Professor of Medicine at the Duke University School of Medicine.
Early in his career, Dr. Sexton spent two years as an Epidemic Intelligence Service Officer at the CDC. In addition to 11 years of experience in private practice in Oklahoma City, Dr. Sexton also worked at Monash Medical Center in Melbourne Australia while on sabbatical in 1989. He was made an honorary lifetime member of the Australasian Society for Infectious Diseases in 2006.
Dr. Sexton has had a direct role in the training of numerous medical students, residents, fellows and postdoctoral students during the 26 years he has been on the Duke faculty. Fourteen of 20 fellows who worked under Dr. Sexton’s supervision are currently hospital epidemiologists and active in research related to HAIs.
Dr. Sexton is one of five Editors in Chief of the Infectious Disease section of UpToDate. He has published more than 200 peer reviewed original manuscripts. He is a recipient of the Clinician Award from the Infectious Diseases Society of America and was previously the Chair of the IDSA Clinical Affairs Committee and served on the IDSA Board of Directors and the Board of the National Foundation for Infectious Diseases.
Dr. Sexton has received the Golden Apple Teaching Award from the Duke University School of Medicine, a Golden Apple Award from the American Medical School Student Association, The Eugene Stead Award for Excellence in Teaching from the Duke Medicine Housestaff (twice) and was named a Master Clinician Teacher by the Duke University School of Medicine in 2011.
Dr. Sexton’s multiple research interests include the risk factors, outcomes and definition of healthcare-associated bloodstream and surgical site infections, risk factors and outcomes of infections due to Staphylococcus aureus and criteria, outcomes and complications of infective endocarditis. He founded the Duke Infection Control Outreach Network in 1997 that has since grown to include 43 community hospitals in 6 states. Dr. Sexton is currently the principal investigator on one of 5 epicenter grants awarded by the Centers for Disease Control, and the PI for grants from The Duke Foundation and the CDC Foundation related to the Duke Antimicrobial Stewardship Outreach network which he founded in 2013.
Matt Stuckert, Vice President of Sales, is a senior sales executive with almost twenty years of successful experience leading high performance sales teams, launching new medical devices, and creating new markets, including: ChloraPrep® skin antiseptics, StatLock® catheter securement devices, and other unique products focused in Infection Prevention, Vascular Access, and Surgery. Matt joined Magnolia Medical Technologies as Vice President of Sales in June 2017, and is responsible for the US Sales organization.
Most recently, Matt served as Vice President of Business Development for San Francisco-based startup Applied Silver, leading the market introduction of their innovative silver-ion technology for the antimicrobial treatment of healthcare textiles.
Prior to Applied Silver, Matt served as Director of Corporate Accounts at Becton Dickinson (BD) via their acquisition of CareFusion. As Director of Corporate Accounts, he drove business growth across seven matrixed business units, working with the most complex healthcare systems in the country. Prior to BD’s acquisition of CareFusion, Matt served as Vice President of Sales, Eastern US & Canada, Vascular & Surgical Products for both CareFusion and its parent-company, Cardinal Health. In this role, Matt led a sales and clinical organization of over 70 direct/indirect reports to deliver over $400M in revenue. During this time Matt was awarded Vice-President-of-the-Year honors multiple times.
Prior to CareFusion, Matt was a key member of the initial sales management team for Enturia (acquired by Cardinal Health) where he led the successful market launch of ChloraPrep®, a novel line of skin antiseptic products, from startup to over $200M in sales. Matt’s strong leadership and sales performance earned him Manager-of-the-Year honors multiple times. Enturia was sold to Cardinal Health for $500M in 2008.
Before Enturia, Matt was one of the first members of the sales organization for San Diego-based startup, Venetec Intl. where he played a key role in the successful market launch and creating a new market for StatLock®, a new line of catheter securement devices. Venetec was ultimately sold to C.R. Bard. Matt holds a BS degree from Pennsylvania State University.
Bob Gerberich, Chief Commercial Officer, is a results-driven global business leader with over 25 years of experience in the surgical and medical device segments of the life sciences market. As a senior sales and marketing executive, he has an exceptional track record of success building new markets and driving rapid commercial growth from product introduction through broad scale adoption. Bob joined Magnolia Medical Technologies as Chief Commercial Officer in April 2017. He is responsible for leading all commercial and customer facing functions of the company.
Most recently, Bob served as Vice President of Sales and Marketing and Vice President of Sales at Invuity, Inc. (NASDAQ: IVTY). Under his direct commercial leadership, Invuity transformed into a rapid growth direct sales-driven advanced surgical photonics company leading the advancement of open minimal access surgery. Bob led the company from a $3 million to $50 million revenue run rate, delivering 17 consecutive quarters of quarter-over-quarter sales growth. He also drove the creation, launch and implementation of strategic marketing and partnership programs. The commercial impact of these programs supported the successful Initial Public Offering (IPO) of the company in June of 2015.
Prior to Invuity, Bob served as President of UltraShape North America and Head of Global Sales for UltraShape Ltd (acquired by Syneron Medical Ltd. [NASDAQ: ELOS]), where he established the North American subsidiary for UltraShape and launched the first non-surgical focused ultrasound body sculpting technology in the world.
Before UltraShape, Bob was Vice President of Sales and Marketing and Vice President of Sales for Thermage, Inc. (now Solta Medical, a division of Valeant Pharmaceuticals [NYSE:VRX]), where he led the successful platform launch of a proprietary radio-frequency technology, creating a new market for non-invasive tissue tightening. He built a direct sales organization from the ground up and led the company from $0 to a $50 million revenue run rate.
Earlier in his career, Bob led dynamic and fast-growing sales organizations at several other medical device companies within the hospital markets including INAMED Aesthetics, acquired by Allergan (NYSE: AGN), LySonix Inc., acquired by Mentor Worldwide, division of J&J (NYSE: JNJ), Leibinger L.P. acquired by Stryker (NYSE: SYK)], and Davol Inc. Blood Mgmt. Group subsidiary of CR Bard (NYSE: BCR). Bob holds a BS. in Marketing from Illinois State University.
Greg Bullington, Chief Executive Officer and co-founder, has led all commercial aspects of company development since inception including clinical trial design and execution, peer-reviewed publications, product development, manufacturing, commercial launch and overall intellectual property strategy. To date, Greg has raised over $60 million in capital to drive the successful growth and development of the company.
Greg has extensive experience in the healthcare industry having led product commercialization and strategy engagements for a wide variety of companies in the biotech (novel immunotherapy), healthcare insurance, wellness and enterprise software sectors.
Greg began his career in professional services with Deloitte & Touche LLP. He continued his professional development as a management consultant with Lake Partners, a Seattle-based strategy firm. In 2006, Greg founded Forum Ventures, a technology commercialization consultancy focused on accelerating the growth of early and mid-stage technology companies.
Over the past 18 years, Greg has led engagements and worked with senior executive teams at over 50 companies ranging from Fortune 100 corporations to venture-backed and early stage startups as a consultant, advisor, and investor. Additionally, Greg has significant intellectual property expertise and is the first named inventor on more than 40 issued patents, as well as over 50 pending US and international patent applications.
Dr. Richard Patton, co-founder, is a board-certified pathologist with more than 40 years of active practice experience. Recognizing the patient safety and financial implications of false positive blood cultures, he has long been interested in exploring opportunities to reduce contamination rates.
In 2006, Dr. Patton designed a clinical trial to test the effectiveness of Initial Specimen Diversion Technique (ISDT), an innovation that he conceived earlier in his career. The results of the trial were significantly positive and published in the peer-reviewed Journal of Clinical Microbiology.
Dr. Patton’s areas of expertise are clinical microbiology, gastrointestinal pathology, and cytopathology. He was the Chief of Pathology and Medical Director of Clinical Laboratories at Northwest Hospital, Seattle, Washington for four decades. He has served as a Laboratory Inspector, Washington State Commissioner, NW Regional Commissioner, and Accreditation and Complaints Committee Member for the College of American Pathologists Laboratory Accreditation Program.